Afatinib CAS 439081-18-2 Purity >99.5% (HPLC) Factory

Short Description:

Chemical Name: Afatinib

Synonyms: BIBW2992 

CAS: 439081-18-2

Purity: >99.5% (HPLC) 

Appearance: Off-White Powder 

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name Afatinib 
Synonyms BIBW2992; BIBW-2992; BIBW2992 Free Base; Tomtovok; (S,E)-N-(4-(3-Chloro-4-Fluorophenylamino)-7-(Tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(Dimethylamino)but-2-Enamide
CAS Number 439081-18-2
CAT Number RF-PI2033
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C24H25ClFN5O3
Molecular Weight 485.94
Solubility Soluble in DMSO
Density 1.380
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Off-White Powder
Identification HPLC, NMR
Purity / Analysis Method >99.5% (HPLC)  
Melting Point 100.0~102.0℃
Loss on Drying <0.50%
Residue on Ignition <0.20%
Total Impurities <0.50%
Heavy Metals ≤20ppm
NMR Spectrum Conforms to Structure
Test Standard Enterprise Standard
Shelf Life 24 Months if Stored Properly
Usage API; Afatinib; Afatinib Dimaleate; NSCLC

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

Afatinib, also known as BIW-2992, (CAS: 439081-18-2) is the second-generation potent and irreversible dual inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinase, developed by Boehringer Ingelheim, Germany. It is capable of irreversibly inhibiting the activity of the tyrosine kinase by undergoing the Michael reaction with the thiol group of cysteine at position 797 of the EGFR. On July 12, 2013, it became a new drug for anti-small cell lung cancer approved by the US FDA under the trade name of Gilotrif. This drug is a tablet. It is used for the treatment of the patients diagnosed with metastatic non-small cell lung cancer (NSCLC) with the loss of the 19th exon or L858R mutation in the 21th exon of the tumor epidermal growth factor receptor (EGFR) confirmed using the kit approved by FDA. The drug is also effective in the treatment of HER2-positive patients with advanced breast cancer. Afatinib belongs to a class of drugs known as tyrosine kinase inhibitors. Tyrosine kinase inhibitors are designed to block the action of a specific enzyme called tyrosine kinase. This enzyme plays a big role in the function of cells, and is active in promoting tumor growth and progression. Afatinib works to inhibit the function of two types of tyrosine kinases: epidermal growth factor receptor (EGFR) and Her2, which are "over-expressed" by several types of cancer. By blocking the function of these tyrosine kinases, Afatinib may prevent cancer cells from dividing and growing.

  • Write your message here and send it to us